Peer Mohamed B, Prabhakar P
Department of Paediatric Neurology, Great Ormond Street Hospital, London, UK.
Neuropediatrics. 2009 Oct;40(5):243-4. doi: 10.1055/s-0030-1247524. Epub 2010 Mar 10.
Levetiracetam is one of the newer anti-epileptic medications, which is now widely used in the treatment of childhood epilepsy. Thrombocytopenia is not a well-known adverse effect of this medication. There have only been two adult case reports describing this feature as an adverse effect of levetiracetam. We describe this feature in a child. A six and half-year-old boy developed symptomatic epilepsy secondary to cerebral venous sinus thrombosis. He was treated with levetiracetam. He made a good recovery from his primary illness, but five weeks after he started taking levetiracetam, he presented with thrombocytopenia requiring platelet transfusion. Extensive investigations for known causes of thrombocytopenia were negative. Withdrawal of levetiracetam led to the resolution of thrombocytopenia. Levetiracetam-induced thrombocytopenia is a rare, but significant adverse effect.
左乙拉西坦是较新的抗癫痫药物之一,目前广泛用于治疗儿童癫痫。血小板减少症并非该药物广为人知的不良反应。仅有两例成人病例报告将此特征描述为左乙拉西坦的不良反应。我们在此描述一名儿童出现的这一特征。一名六岁半的男孩因脑静脉窦血栓形成继发症状性癫痫。他接受了左乙拉西坦治疗。他的原发性疾病恢复良好,但在开始服用左乙拉西坦五周后,出现血小板减少症,需要输注血小板。对已知血小板减少症病因的广泛检查均为阴性。停用左乙拉西坦后血小板减少症得到缓解。左乙拉西坦诱导的血小板减少症是一种罕见但严重的不良反应。